Literature DB >> 7971632

Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine.

C Montalban1, F Liaño, A Aguilera.   

Abstract

Fludarabine is one of the most recent and promising therapeutic agents for chronic lymphocytic leukaemia. We describe a patient who developed tumour lysis syndrome after the first course of treatment with fludarabine and call attention to this uncommon but potentially lethal complication that has not been previously taken into account in this neoplasia. It should always be anticipated when patients are treated with new and effective drugs.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7971632      PMCID： PMC2397734          DOI： 10.1136/pgmj.70.827.651

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  10 in total

1.  Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.

Authors:  J R Redman; F Cabanillas; W S Velasquez; P McLaughlin; F B Hagemeister; F Swan; M A Rodriguez; W K Plunkett; M J Keating
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

2.  Fludarabine and acute tumor lysis in chronic lymphocytic leukemia.

Authors:  J N Frame; W L Dahut; S Crowley
Journal:  N Engl J Med       Date:  1992-11-05       Impact factor: 91.245

3.  Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate.

Authors:  A F List; T D Kummet; J D Adams; H G Chun
Journal:  Am J Med       Date:  1990-09       Impact factor: 4.965

4.  Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.

Authors:  M J Keating; H Kantarjian; M Talpaz; J Redman; C Koller; B Barlogie; W Velasquez; W Plunkett; E J Freireich; K B McCredie
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

5.  Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

Authors:  M J Keating; H Kantarjian; S O'Brien; C Koller; M Talpaz; J Schachner; C C Childs; E J Freireich; K B McCredie
Journal:  J Clin Oncol       Date:  1991-01       Impact factor: 44.544

6.  A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study.

Authors:  L Elias; D Stock-Novack; D R Head; M R Grever; J K Weick; R A Chapman; J E Godwin; E N Metz; F R Appelbaum
Journal:  Leukemia       Date:  1993-03       Impact factor: 11.528

Review 7.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

8.  Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide.

Authors:  R D McCroskey; D F Mosher; C D Spencer; E Prendergast; W L Longo
Journal:  Cancer       Date:  1990-07-15       Impact factor: 6.860

9.  Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.

Authors:  L Bergmann; K Fenchel; B Jahn; P S Mitrou; D Hoelzer
Journal:  Ann Oncol       Date:  1993-05       Impact factor: 32.976

10.  Acute tumor lysis syndrome in prolymphocytic leukemia.

Authors:  G A Gomez; T Han
Journal:  Arch Intern Med       Date:  1987-02
  10 in total
  1 in total

Review 1.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.